CGD Policy Blogs
As the world battles COVID-19, practical investments are urgently needed to ensure that decision-makers consult the best and most relevant evidence on COVID-19 before making a decision.
With a focus on tests, treatments, and a vaccine, we take a look at the emerging global clinical and economic evidence-base underpinning some of these technologies, the mechanisms (mostly global) for financing these commodities, and, finally, the decision-making processes for selecting technologies. This includes identifying the right subpopulations and negotiating a cost-effective tiered price across countries and regions.
This blog focuses on hospital treatment for COVID-19 patients in low-resource-settings, considering what we know about the spectrum of COVID-19 illness and what this tells us about where resources might best be focused in low-resource-settings. As elsewhere, decision makers, global and local, must prioritise resourcing and capacity development for the ward-level care and simple oxygen therapy that most hospitalised COVID-19 patients will need—not the high-end clinical care that may well be impossible to scale-up in time in countries with limited resources.